Erste Asset Management GmbH Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Erste Asset Management GmbH acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 40,000 shares of the biotechnology company’s stock, valued at approximately $305,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Counterweight Ventures LLC raised its position in shares of BioCryst Pharmaceuticals by 591.7% during the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock valued at $710,000 after purchasing an additional 79,884 shares during the period. XTX Topco Ltd raised its position in shares of BioCryst Pharmaceuticals by 299.0% during the 2nd quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company’s stock valued at $970,000 after purchasing an additional 117,607 shares during the period. Seven Eight Capital LP raised its position in shares of BioCryst Pharmaceuticals by 1,407.1% during the 2nd quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock valued at $1,048,000 after purchasing an additional 158,358 shares during the period. Rice Hall James & Associates LLC raised its position in shares of BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after purchasing an additional 84,102 shares during the period. Finally, Principal Financial Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after purchasing an additional 375,890 shares during the period. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Up 1.9 %

Shares of NASDAQ:BCRX opened at $7.33 on Thursday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.88. The stock has a market capitalization of $1.52 billion, a P/E ratio of -12.02 and a beta of 1.79. The firm has a fifty day simple moving average of $7.58 and a two-hundred day simple moving average of $7.32.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. During the same period in the previous year, the business earned ($0.19) earnings per share. The business’s quarterly revenue was up 35.1% on a year-over-year basis. On average, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Barclays lifted their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.